IRIS
MILANI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.754
EU - Europa 1.136
AS - Asia 590
AF - Africa 6
OC - Oceania 4
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.495
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.747
IE - Irlanda 657
CN - Cina 535
FI - Finlandia 153
DE - Germania 98
IT - Italia 83
UA - Ucraina 48
SE - Svezia 43
JP - Giappone 22
AT - Austria 14
IN - India 13
GB - Regno Unito 12
SG - Singapore 9
CA - Canada 7
FR - Francia 7
BE - Belgio 5
IR - Iran 5
AU - Australia 4
MU - Mauritius 4
CL - Cile 3
CZ - Repubblica Ceca 3
HK - Hong Kong 3
ES - Italia 2
EU - Europa 2
GR - Grecia 2
NL - Olanda 2
RU - Federazione Russa 2
CH - Svizzera 1
DK - Danimarca 1
EG - Egitto 1
LU - Lussemburgo 1
MY - Malesia 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
TR - Turchia 1
Totale 3.495
Salva come PNG Salva come JPEG
Città #
Dublin 657
Chandler 517
Ashburn 158
Nanjing 139
Helsinki 103
Jacksonville 97
Princeton 97
Lawrence 92
Beijing 84
Medford 81
Wilmington 70
Nanchang 57
Shanghai 52
Hebei 37
Shenyang 37
Ann Arbor 34
Changsha 33
Pavia 32
Jiaxing 31
Piscataway 28
Norwalk 24
Tokyo 21
Tianjin 19
New York 18
Hangzhou 16
Woodbridge 15
Seattle 13
Washington 13
Boardman 12
Pune 12
Induno Olona 11
Los Angeles 10
Fairfield 9
Milan 9
Singapore 8
Tamm 7
Zhengzhou 7
Houston 6
Redwood City 6
Vienna 6
Brussels 5
Falkenstein 5
Ningbo 5
Cagliari 4
Berlin 3
Brno 3
Catania 3
Detroit 3
Sydney 3
Toronto 3
Andover 2
Athens 2
Bari 2
Bologna 2
Borås 2
Dearborn 2
Des Moines 2
Fuzhou 2
Kunming 2
Latisana 2
Markham 2
Nagold 2
San Francisco 2
Taizhou 2
Torino 2
Vinovo 2
Altoona 1
Ardabil 1
Baltimore 1
Cairo 1
Cervera del Rio Alhama 1
Clearwater 1
Copenhagen 1
Forest City 1
Freetown 1
Gunzenhausen 1
Haikou 1
Hanover 1
Jinan 1
Kemerovo 1
Kish 1
Las Vegas 1
Leawood 1
London 1
Lugano 1
Luxembourg 1
Melbourne 1
Moscow 1
Munich 1
Orange 1
Ottawa 1
Palermo 1
Riyadh 1
Rockville 1
Rome 1
Sacramento 1
Saint-Alexis-de-Matapedia 1
Sassari 1
Selangor 1
Shiraz 1
Totale 2.781
Salva come PNG Salva come JPEG
Nome #
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 82
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 76
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 72
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 66
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 64
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 64
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 63
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 62
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 61
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 57
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 56
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 56
A patient with AL amyloidosis with negative free light chain results 55
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 54
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 54
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 52
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 51
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 51
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 49
Prognostication of survival and progression to dialysis in AA amyloidosis 48
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 47
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 46
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 45
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 44
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 43
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 43
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 43
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 42
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 42
Attitudes about when and how to treat patients with AL amyloidosis: an international survey 42
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 41
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 40
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions 40
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 40
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 40
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 40
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 38
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 38
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. 37
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts 37
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 37
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 37
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 36
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 35
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis 35
A practical approach to the diagnosis of systemic amyloidoses 35
The use of mass spectrometry for the diagnosis of plasma cell dyscrasias: focus on light chain (AL) amyloidosis patterns. 34
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma 33
The lung in amyloidosis 33
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance 33
Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis 32
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 32
Management of AL amyloidosis in 2020 32
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 31
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis 31
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 31
Predicting survival in light chain amyloidosis 31
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients 31
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 31
null 30
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 30
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 30
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 30
null 29
Conventional Therapy for Amyloid Light-Chain Amyloidosis 29
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 29
null 28
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 28
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 28
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 27
Novel strategies for the diagnosis and treatment of cardiac amyloidosis 27
A powerful oral triplet for AL amyloidosis 27
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 27
Management of AL amyloidosis in 2020 26
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 25
The next generation of novel therapies for the management of relapsed multiple myeloma 25
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 25
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis 25
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 24
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 24
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 23
Monoclonal IgM-related AL amyloidosis 23
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 22
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 22
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis 22
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 21
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 21
A case of monoclonal gammopathy of renal significance 21
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 20
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 20
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis 20
Search for AL amyloidosis risk factors using Mendelian randomization 20
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 20
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 19
Management of the elderly patient with AL amyloidosis 18
Novel Therapies in Light Chain Amyloidosis 18
Parkinsonism and dysautonomia: Multiple system atrophy? 18
New concepts in the treatment and diagnosis of amyloidosis 16
Light chain amyloidosis 16
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 14
Totale 3.618
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.604
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.604
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020588 156 234 0 12 2 10 7 12 2 62 29 62
2020/2021217 26 8 10 15 2 15 6 44 56 18 13 4
2021/2022408 5 2 12 0 12 6 6 33 23 21 53 235
2022/20231.557 165 141 20 85 108 133 14 82 748 11 33 17
2023/2024673 80 137 32 50 61 134 17 37 6 25 49 45
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 3.698